Hendershot Cowart P.C. is proud to share that we have been recognized in the 2026 JD Supra Readers’ Choice Awards – a distinction based on real reader engagement, not self-nomination. Attorney Keith Lefkowitz has been named a Top Author in Healthcare, and our article “FDA Update: Current Guidelines for Semaglutide and Tirzepatide Compounding” was recognized as a Top Read Article in Life Sciences.
About the JD Supra Readers’ Choice Awards
JD Supra’s Readers’ Choice Awards recognize the authors and firms whose work generated the highest levels of visibility and engagement among C-suite executives, in-house counsel, media, and other professionals throughout 2025. This year’s awards span 33 key cross-industry topics, with 10 authors and one firm recognized per category – selected from more than 70,000 professionals who publish on the platform.
Unlike peer-reviewed rankings, the Readers’ Choice Awards reflect actual reader behavior: which articles were read, shared, and engaged with most throughout the year. Earning recognition means the content reached and resonated with the professionals who needed it.
Keith Lefkowitz: Top Author in Healthcare
Attorney Keith Lefkowitz focuses his practice on healthcare law and regulatory compliance. He regularly counsels physicians, medical practices, and healthcare businesses on matters including FDA, Anti-Kickback Statute, and Stark Law compliance; False Claims Act defense; healthcare transactions and medical practice set-ups; and Texas Medical Board licensing issues.
His recognition as a Top Author reflects a consistent body of practical, timely legal guidance regularly shared on this website and JD Supra – written for the healthcare professionals and business leaders navigating a rapidly shifting regulatory landscape.
Top Read Article: FDA Update on Semaglutide and Tirzepatide Compounding
The recognized article addresses one of the most closely watched regulatory developments in healthcare in 2025: FDA guidance on the compounding of semaglutide and tirzepatide, the active ingredients in medications like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®.
As the FDA moved to remove these drugs from its shortage list, compounding pharmacies, medical spas, and prescribing physicians faced real uncertainty about what was and was not permitted. The article provided clear, actionable guidance on what the FDA’s position meant in practice, and it reached a significant national audience as a result.
If your practice or business has questions about compounding compliance, our healthcare attorneys are available to help. Contact us at (713) 783-3110 to schedule a consultation.
We congratulate Keith on this latest recognition. Thank you to the JD Supra readers whose engagement made it possible.